Acute-Phase Reactants and Coronary Heart Disease

Wolfgang Koenig; Robert S. Rosenson

doi:10.1055/s-2002-36770

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2002; 02(4): 417-428
DOI: 10.1055/s-2002-36770

Acute-Phase Reactants and Coronary Heart Disease

Wolfgang Koenig¹ , Robert S. Rosenson²

¹Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
²Preventive Cardiology Center, Departments of Medicine and Preventive Medicine, Northwestern University Medical School, Chicago, Illinois

Abstract

ABSTRACT

Inflammation is considered to play an essential role in the initiation, progression, and the final pathophysiological steps of atherosclerosis, plaque erosion or fissure, and eventually plaque rupture. Prospective studies have identified several markers of systemic inflammation that are predictors of future cardiovascular events, not only in apparently healthy subjects, but also in patients with unstable angina and previous myocardial infarction. Measurement of inflammatory markers may add to the predictive value of total and high-density lipoprotein cholesterol in assessing coronary risk long-term. Various biological mechanisms exist that could explain the pathological effects of these inflammatory molecules. Finally, the results from recent clinical trials indicate that the net benefit of various compounds in primary and secondary prevention of coronary heart disease, like aspirin, statins, and ACE inhibitors, may be mediated, at least in part, by modifying the consequences of the inflammatory response on vascular risk. However, further studies are required to address these associations because the mechanisms that cause an inflammatory response are only incompletely understood and deserve further investigation.

KEYWORD

Acute-phase reactants - coronary heart disease risk - prospective epidemiological studies - mechanisms - modulation of the inflammatory response

Full Text

References

REFERENCES

1 Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med . 1999; 340 448-454
2 Friedman G D, Klatsky A L, Siegelaub A B. The leukocyte count as a predictor of myocardial infarction. N Engl J Med . 1974; 290 1275-1278
3 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA . 1998; 279 1477-1482
4 Olivares R, Ducimetiere P, Claude J R. Monocyte count: a risk factor for coronary heart disease?. Am J Epidemiol . 1993; 127 49-53
5 Danesh J, Collins R, Peto R, Lowe G DO. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J . 2000; 21 525-520
6 Erikssen G, Liestøl K, Bjørnholt J V. Erythrocyte sedimentation rate: possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J . 2000; 21 1614-1620
7 Macy E, Hayes T, Tracy R P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem . 1997; 43 52-58
8 Hutchinson W L, Koenig W, Fröhlich M. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem . 2000; 46 934-938
9 Kuller L H, Tracy R P, Shaten J, Meilahn E N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol . 1996; 144 537-554
10 Tracy R P, Lemaitre R N, Psaty B M. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol . 1997; 17 1121-1127
11 Ridker P M, Cushman M, Stampfer M J. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med . 1997; 336 973-979
12 Koenig W, Sund M, Fröhlich M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease). Augsburg Cohort Study, 1984 to 1992. Circulation . 1999; 99 237-242
13 Danesh J, Whincup P, Walker M. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ . 2000; 321 199-204
14 Ridker P M, Buring J E, Shih J. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation . 1998; 98 731-733
15 Ridker P M, Hennekens C H, Buring J E, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med . 2000; 342 836-843
16 Strandberg T E, Tilvis R S. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol . 2000; 20 1057-1060
17 Jager A, van Hinsbergh W M V, Kostense P J. Von Willebrand's factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study. Arterioscler Thromb Vasc Biol . 1999; 19 3071-3078
18 Ridker P M, Glynn R J, Hennekens C H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation . 1998; 97 2007-2011
19 Mendall M A, Strachan D P, Butland B K. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J . 2000; 21 1584-1590
20 Lowe G DO, Yarnell J WG, Rumley A, Bainton D, Sweetnam P M. C-reactive protein, D-dimer, and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis?. Arterioscler Thromb Vasc Biol . 2001; 21 603-610
21 Packard C J, O'Reilly D SJ, Caslake M J, for the West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med . 2000; 343 1148-1155
22 Nelson J J, Liao D, Sharrett A R. Serum albumin level as a predictor of incident coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol . 2000; 151 468-477
23 Lindgarde F, Lind P, Hedblad B. Incidence of myocardial infarction and death in relation to plasma levels of inflammatory sensitive proteins. A long-term cohort study. Circulation . 1998; 98(suppl) abstract
24 Muscari A, Bozzoli C, Puddu G M. Association of serum C3 levels with the risk of myocardial infarction. Am J Med . 1995; 98 357-364
25 Lindberg G, Råstam L, Gullberg B, Eklund G A. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54358 men and women during 20.5-year follow-up. Int J Epidemiol . 1992; 21 253-257
26 Taniuchi K, Chifu K, Hayashi N. A new enzymatic method for determination of sialic acid in serum and its application for a marker of acute phase reactants. Kobe J Med Sci . 1981; 27 91-102
27 Langer R D, Criqui M H, Feigelson H S, McCann T J, Hamburger R N. IgE predicts future nonfatal myocardial infartion in men. J Clin Epidemiol . 1996; 49 203-209
28 Kovanen P T, Manttari M, Palosuo T, Manninen V, Aho K. Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med . 1998; 158 1434-1439
29 Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert A K. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation . 2000; 102 2576-2581
30 Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation . 2000; 102 1082-1085
31 Folsom A R, Wu K K, Rosamond W D, Sharrett A R, Chambless L E. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation . 1997; 96 1102-1108
32 Mendall M A, Patel P, Asante M. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart . 1997; 78 273-277
33 Ridker P M, Rifai N, Stampfer M J, Hennekens C H. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among healthy men. Circulation . 2000; 101 1767-1772
34 Harris T B, Ferruci L, Tracy R P. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med . 1999; 106 506-512
35 Volpato S, Guralnik J M, Ferruci L. Cardiovascular disease, Interleukin-6, and risk of mortality in older women. The Women's Health and Aging Study. Circulation . 2001; 103 947-953
36 Ridker P M, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation . 2000; 101 2149-2153
37 Hwang S J, Ballantyne C M, Sharrett A R. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk In Communities (ARIC) Study. Circulation . 1997; 96 4219-4225
38 De Lemos A J, Hennekens C H, Ridker P M. Plasma concentrations of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol . 2000; 36 423-426
39 Ridker P M, Hennekens C H, Roitman-Johnson B, Stampfer M, Allen J. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet . 1998; 351 88-92
40 Ridker P M, Buring J E, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation . 2001; 103 491-495
41 Malik I, Danesh J, Whincup P. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet . 2001; 358 971-975
42 Haverkate F, Thompson S G, Pyke S DM, Gallimore J R, Pepys M B. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet . 1997; 349 462-466
43 Hasdai D, Scheinowitz M, Leibovitz E. Increased serum concentrations of interleukin-1β in patients with coronary artery disease. Heart . 1996; 76 24-28
44 Wallén N H, Held C, Rehnqvist N, Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or nonfatal myocardial infarction. Eur Heart J . 1999; 20 1039-1043
45 Braunwald E. Unstable angina. An etiologic approach to management. Circulation . 1998; 98 2219-2222
46 Berk B C, Weintraub W S, Alexander R W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol . 1990; 65 168-172
47 Liuzzo G, Biasucci L M, Gallimore J R. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med . 1994; 331 417-424
48 Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation . 1997; 96 4204-4210
49 Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med . 2000; 343 1139-1147
50 Verheggen P H M W, de Maat P M M, Cats V M. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J . 1999; 20 567-574
51 Rebuzzi A G, Quaranta G, Liuzzo G. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol . 1998; 82 715-719
52 Morrow D A, Rifai N, Antman E M. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A Substudy. J Am Coll Cardiol . 1998; 31 1460-1465
53 Heeschen C, Hamm C W, Bruemmer J, Simoons M L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial. J Am Coll Cardiol . 2000; 35 1535-1542
54 Biasucci L M, Liuzzo G, Grillo R L. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation . 1999; 99 855-860
55 Ferreiros E R, Boissonnet C P, Pizarro R. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation . 1999; 100 1958-1963
56 Liuzzo G, Buffon A, Biasucci L M. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation . 1998; 98 2370-2376
57 Biasucci L M, Vitelli A, Liuzzo G. Elevated levels of interleukin-6 in unstable angina. Circulation . 1996; 94 874-877
58 Liuzzo G, Biasucci L M, Rebuzzi A G. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation . 1996; 94 2373-2380
59 Mazzone A, De Servi S, Ricevuti G. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation . 1993; 88 358-363
60 Dinerman J L, Mehta J L, Saldeen T GP. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol . 1990; 15 1559-1563
61 Haught W H, Mansour M, Rothlein R. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am Heart J . 1996; 132 1-6
62 Serneri G GN, Abbaate R, Gori A M. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation . 1992; 86 790-797
63 Jude B, Agraou B, McFadden E P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation . 1994; 90 1662-1668
64 Kai H, Ikeda H, Yysukawa H. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol . 1998; 32 368-372
65 Mulvihill N T, Foley J B, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol . 2000; 36 1210-1216
66 Caligiuri G, Liuzzo G, Biasucci L M, Maseri A. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol . 1998; 32 1295-1304
67 Blum A, Vardinon N, Kaplan G. Autoimmune and inflammatory responses may have an additive effect in postpercutaneous transluminal coronary angioplasty restenosis. Am J Cardiol . 1998; 81 339-341
68 Sturk A, Hack C E, Aarden L A. Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. J Lab Clin Med . 1992; 119 574-579
69 Neumann F J, Ott I, Gawaz M. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation . 1995; 92 748-755
70 Rosenson R S. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol . 1993; 22 933-940
71 Kukielka G L, Smith W, Manning A M. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation . 1995; 92 1866-1875
72 Marx N, Neumann F J, Ott I. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol . 1997; 30 165-170
73 Barron H V, Cannon C P, Murphy S A, Braunwald E, Gibson C M. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction. A Thrombolysis in Myocardial Infarction 10 Substudy. Circulation . 2000; 102 2329-2334
74 Cooper H A, Exner D V, Waclawiw M A, Domanski M J. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the studies of left ventricular dysfunction (SOLVD)). Am J Cardiol . 1999; 84 252-257
75 Gwechenberger M, Mendoza L H, Youker K A. Cardiac myocytes produce Interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation . 1999; 99 546-551
76 Lagrand W K, Niessen H WM, Wolbink G J. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation . 1997; 95 97-103
77 Pietilä K O, Harmoinen A P, Jokiniitty J, Pasternack A I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 4 months of follow-up in patients under thrombolytic treatment. Eur Heart J . 1996; 17 1345-1349
78 Anzai T, Yoshikawa T, Shiraki H. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation . 1997; 96 778-784
79 Milazzo D, Biasucci L, Luciani N. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol . 1999; 84 459-461
80 Eisenberg M S, Chen H J, Warshofsky M K. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation . 2000; 102 2100-2104
81 Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?. Kidney Int . 2001; 59 407-414
82 Ernst E, Hammerschmidt D E, Bagge U, Matrai A, Dormandy J A. Leukocytes and the risk of ischemic diseases. JAMA . 1987; 257 2318-2324
83 Koenig W. Fibrinogen and coronary risk. In: Fuster V, ed. Current Review of Cardiology I Philadelphia: Current Science Inc 1999: 112-118
84 Torzewski M, Rist C, Mortensen R F. C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol . 2000; 20 2094-2099
85 Zwaka T P, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation . 2001; 103 1194-1197
86 Cermak J, Key N S, Bach R R. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood . 1993; 82 513-520
87 Clausen P, Jensen J S, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation . 2001; 103 1869-1874
88 Miles L A, Fless G M, Levin E G, Scanu A M, Plow E F. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature . 1989; 339 301-303
89 Koenig W, Sund M, Döring A, Ernst E. Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity. Results from a large population sample. Circulation . 1997; 95 335-341
90 Smith J K, Dykes R, Douglas J E, Krishnaswamy G, Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA . 1999; 281 1722-1727
91 DeMaat M P, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis . 1996; 121 185-191
92 Ditschuneit H H, Flechtner-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res . 1995; 3 43-48
93 Imhof A, Fröhlich M, Brenner H. Effect of alcohol consumption on systemic markers of inflammation. Lancet . 2001; 357 763-767
94 Rosenson R S, Tangney C C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA . 1998; 279 1643-1650
95 Ridker P M, Rifai N, Pfeffer M A. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation . 1998; 98 839-844
96 Ridker P M, Rifai N, Pfeffer M A. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation . 1999; 100 230-235
97 Albert M A, Danielson E, Rifai N, Ridker P M, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA . 2001; 286 64-70
98 Ridker P M, Rifai N, Pitman Lowenthal S. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation . 2001; 103 1191-1193
99 Ridker P M, Rifai N, Clearfield M. for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med . 2001; 344 1959-1965
100 Staels B, Koenig W, Habib A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature . 1998; 393 790-793
101 Delerive P h, Gervois P h, Fruchart J C, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem . 2000; 275 36703-36707
102 Husain S, Andrews N P, Mulcahy D, Panza J, Quyyumi A A. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation . 1998; 97 716-720
103 Kopp E, Shosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science . 1994; 265 956-959
104 Weber C, Erl W, Pietsch A, Weber P C. Aspirin inhibits Nuclear Factor-κB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation . 1995; 91 1914-1917
105 Grainger D J, Kemp P R, Metcalfe J C. The serum concentration of active transforming growth factor-β is severly depressed in advanced atherosclerosis. Nature Med . 1995; 1 74-79
106 Feldmann M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol . 2001; 37 2036-2041
107 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk individuals. N Engl J Med . 2000; 342 145-153
108 Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation . 2001; 104 365-372
109 Anderson J L, Muhlestein J B, Carlquist J. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumonia infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation . 1999; 99 1540-1547